Core Viewpoint - Oulin Bio is accelerating its expansion efforts by raising 175 million RMB to invest in the technological transformation of its vaccine R&D and production base to enhance production efficiency and product quality in response to growing market demand [2][3] Group 1: Fundraising and Investment - Oulin Bio plans to raise a total of 175 million RMB through a simplified procedure for issuing ordinary shares, which will be invested in a vaccine R&D production base technological transformation project [2][3] - The total investment for the vaccine R&D production base technological transformation project is 290 million RMB, with a planned implementation period of four years [3] - The project will upgrade production workshops for key products, including the tetanus workshop, polysaccharide workshop, and freeze-drying workshop, and will involve technical upgrades to related facilities and equipment [3] Group 2: Company Background and Performance - Founded in 2009, Oulin Bio specializes in the R&D, production, and sales of human vaccines and was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in 2021 [2][5] - The company has achieved steady growth, with its core product, the adsorbed tetanus vaccine, maintaining a leading market share in China, generating sales revenue of 535.8 million RMB in 2024, a year-on-year increase of 15.7% [5] - In the first quarter of 2025, Oulin Bio continued its growth trend, achieving revenue of 87.49 million RMB, a year-on-year increase of 23.58%, while reducing net loss to 7.074 million RMB from 26 million RMB in the same period last year [6] Group 3: R&D Investment and Innovation - Oulin Bio has consistently invested in innovation, with total R&D expenses reaching 470 million RMB from 2020 to 2024 [6] - The company has a strong focus on developing a complete innovation pipeline centered around the "super bacteria vaccine" strategy, particularly in the field of antibiotic-resistant bacteria vaccines [4] - As of 2024, Oulin Bio has 136 R&D personnel, accounting for 28.94% of its total workforce, and has obtained a total of 82 invention patents [6]

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. reported on the usage of funds raised from its initial public offering, detailing the total amount raised, the current balance, and the allocation of these funds for various projects [1][2][3]. Fundraising Overview - The company raised a total of RMB 400,436,400.00 from the issuance of 40,530,000 shares at RMB 9.88 per share, with a net amount of RMB 358,837,273.38 after deducting issuance costs [1]. - As of March 31, 2025, the remaining balance of the raised funds is RMB 100,390,120.43, which accounts for 27.98% of the net amount raised [8]. Fund Storage Situation - The funds are stored in two bank accounts: - RMB 39,859,763.12 at China Merchants Bank - RMB 60,530,357.31 at Industrial Bank, totaling RMB 100,390,120.43 [2]. Actual Usage of Funds - The company has utilized RMB 27,752.20 million of the raised funds, with the following annual breakdown: - 2021: RMB 1,998.69 million - 2022: RMB 9,931.96 million [9]. - The company has adjusted the allocation of funds, redirecting RMB 10,278.30 million initially intended for vaccine projects to clinical research projects [3]. Temporary Idle Funds Management - The company has engaged in cash management for temporarily idle funds, with a maximum daily balance not exceeding RMB 30 million. The investment returns from cash management in 2021, 2022, and 2023 were RMB 3.4968 million, RMB 7.1798 million, and RMB 8.1850 million, respectively [5][6][7]. Economic Benefits from Investment Projects - The report includes a table detailing the economic benefits realized from the investment projects, although specific figures are not provided in the summary [9][12].

Meeting Overview - The sixth session of the Supervisory Board of Chengdu Olin Biological Technology Co., Ltd. was held on June 25, 2025, with all three supervisors present, confirming the legality and validity of the meeting [1]. Resolutions Passed - The Supervisory Board approved the proposal regarding the results of the stock issuance to specific targets, affirming the legality and compliance of the issuance process [2]. - The signing of a subscription agreement with specific targets was approved, ensuring no harm to the interests of the company and its shareholders [2]. - The authenticity, accuracy, and completeness of the fundraising prospectus for the stock issuance were confirmed, with no misleading statements or omissions [2]. - The revised plan for the stock issuance was approved, aligning with relevant laws and the company's specific circumstances [2][4]. - The analysis report for the stock issuance plan was deemed compliant with legal regulations [4]. - The feasibility analysis report for the use of raised funds was approved, confirming its alignment with legal requirements [5]. - The report on the use of previously raised funds as of March 31, 2025, was approved, with an audit report from Zhongqin Wanxin Accounting Firm [5]. - The detailed report on non-operating gains and losses for the last three years and one quarter was approved, with an audit report confirming its compliance [6]. - The internal control evaluation report for the first quarter of 2025 was approved, reflecting the actual internal control situation [7]. - The measures to mitigate the dilution of immediate returns from the stock issuance were approved, along with commitments from relevant parties [8]. - The explanation regarding the fundraising's alignment with technology innovation was approved, confirming its compliance with legal regulations [9]. - The establishment of a dedicated account for the raised funds and the authorization to sign a regulatory agreement was approved, ensuring proper management of the funds [9].

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. is issuing A-shares to specific investors, which may dilute immediate returns, and the company has proposed measures to mitigate this impact [1][5]. Financial Impact Analysis - The company analyzed the impact of the stock issuance on key financial metrics under three scenarios for 2025 net profit compared to 2024: - Scenario 1: 10% increase in net profit results in net profit of 22.83 million yuan and basic earnings per share (EPS) of 0.0558 yuan [3]. - Scenario 2: Net profit remains unchanged at 20.76 million yuan, leading to basic EPS of 0.0507 yuan [4]. - Scenario 3: 10% decrease in net profit results in net profit of 18.68 million yuan and basic EPS of 0.0457 yuan [4]. Necessity and Reasonableness of the Issuance - The funds raised will be used for the "Vaccine R&D Production Base Technology Renovation Project," which aligns with the company's core business and development strategy [5][6]. Company’s Resource and Capability Assessment - The company has a stable management team with extensive experience in the biopharmaceutical industry and is committed to continuous talent development [6][7]. - The R&D team has over ten years of experience in vaccine development, focusing on both traditional and innovative vaccines [7][8]. Measures to Mitigate Dilution of Immediate Returns - The company will maintain stable growth in its main business and accelerate the investment progress of the fundraising projects to enhance profitability [9]. - It will strengthen fundraising management to ensure compliance and effective use of raised funds [11]. - The company plans to improve its profit distribution policy to optimize investor returns [12][13]. Commitments from Major Stakeholders - The controlling shareholders and actual controllers have committed to ensuring the fulfillment of measures to mitigate the dilution of immediate returns [14][15]. - The board of directors and senior management have also made commitments to protect company interests and ensure compliance with regulations [15][16].

关于以简易程序向特定对象发行人民币普通股 证券代码：688319 证券简称：欧林生物 公告编号：2025-022 成都欧林生物科技股份有限公司 （A 股）股票预案（修订稿）披露的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都欧林生物科技股份有限公司（以下简称"公司"）于 2024 年 10 月 29 日召开第六届董事会第十七次会议审议通过了《关于公司以简易程序向特定对象 发行股票预案的议案》等相关议案，于 2025 年 6 月 25 日召开第六届董事会第二 十一次会议通过了《关于公司以简易程序向特定对象发行股票竞价结果的议案》 《关于公司与特定对象签署附生效条件的股份认购协议的议案》等相关议案。 根据公司 2023 年年度股东大会及 2024 年年度股东大会的授权，本次修订预 案无需另行提交公司股东大会审议。 本次以简易程序向特定对象发行股票的预案披露不代表审核、注册部门对于 本次发行股票相关事项的实质性判断、确认或批准，预案所述本次发行相关事项 的生效和完成尚需上海证券交易所审核通过，并经中国证券监督管 ...

证券简称：欧林生物 证券代码：688319 成都欧林生物科技股份有限公司 以简易程序向特定对象发行人民币普通股 （A股）股票预案（修订稿） 二〇二五年六月 公司声明 1、本公司及董事会全体成员保证本预案内容真实、准确、完整，并确认不 存在虚假记载、误导性陈述或重大遗漏，对本预案内容的真实性、准确性、完 整 性承担个别和连带的法律责任。 3、本次以简易程序向特定对象发行股票完成后，公司经营与收益的变化由 公司自行负责；因本次以简易程序向特定对象发行股票引致的投资风险，由投 资 者自行负责。 4、本预案是公司董事会对本次以简易程序向特定对象发行股票的说明，任 何与之相反的声明均属不实陈述。 5、投资者如有任何疑问，应咨询自己的股票经纪人、律师、专业会计师或 其他专业顾问。 6、本预案所述事项并不代表审批机关对于本次以简易程序向特定对象发行 股票相关事项的实质性判断、确认或批准，本预案所述本次以简易程序向特定 对象发行股票相关事项的生效和完成尚待上海证券交易所审核通过并经中国证 监会作出同意注册决定。 2 特别提示 本部分所述词语或简称与本预案"释义"所述词语或简称具有相同含义。 一、本次以简易程序向特定对象发行 ...

成都欧林生物科技股份有限公司 非经常性损益专项审核报告 勤信专字【2025】第 1483 号 _您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://4cc.ocf.gov.cn）"龙f在线 "江西" m 录 | 附件: | | | --- | --- | | 非经常性损益专项审核报告 非经常性损益明细表 | 1-2 3 | 4-8 非经常性损益明细表附注 中勤万信会计师事务所(特殊普通合伙) 地址:北京市西城区西直门外大街 112号阳光大厦 10 层 电话:(86-10) 68360123 传真:(86-10) 68360123-3000 邮编:100044 非经常性损益专项审核报告 勤信专字【2025】第 1483 号 成都欧林生物科技股份有限公司全体股东; 我们接受委托,对后附的成都欧林生物科技股份有限公司(以下简称"欧林生 物")2025年 1-3 月、2024 年度、2023年度、2022 年度的非经常性损益明细表 〈以下简称"非经常性损益明细表"〉进行了专项审核。按照中国证券监督管理委 员会《公开发行证券的公司信息披露解释性公告第 1 号 -- 非经常性损益(2023 年 修订) ...

成都欧林生物科技股份有限公司 内部控制审计报告 勤信审字【2025】 第3231 号 此隔用于证明该审计报告是否由具有执业许可的会计师事务所出畏， "注册会计师行业统…监管平台 (htp://acc mofgov.cn) " 行查验 报告编码 ：京 256RBA1HL C 您可使用手机"扫一扫" 或 进入 目 型 内容 内部控制审计报告 1-2 页次 " 中 勳方信会计师事务所 (特殊普通合伙) 地址:北京西直门外大街 112 号阳光大厦 10 层 电话:(86-10) 68360123 专真:(86-10) 68360123-3000 邮编:100044 内部控制审计报告 動信审字《2025》第 3231 号 成都欧林生物科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了成都欧林生物科技股份有限公司（以下简称"欧林生物"）2025 年 3 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制 评价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是欧林生物 董事会 ...

成都欧林生物科技股份有限公司 证券简称：欧林生物 证券代码：688319 以简易程序向特定对象发行人民币普通股（A 股） 方案论证分析报告 （修订稿） 二〇二五年六月 | 一、本次向特定对象发行的背景和目的 | 2 | | --- | --- | | （一）本次向特定对象发行的背景 | 2 | | （二）本次向特定对象发行的目的 | 4 | | 二、本次发行证券及其品种选择的必要性 | 5 | | （一）本次发行证券的品种 5 | | | （二）本次发行证券的必要性 5 | | | 三、本次发行对象的选择范围、数量和标准的适当性 | 6 | | （一）本次发行对象的选择范围的适当性 | 6 | | （二）本次发行对象的数量的适当性 | 6 | | （三）本次发行对象的标准的适当性 | 7 | | 四、本次发行定价的原则、依据、方法和程序的合理性 | 7 | | （一）本次发行定价的原则及依据 | 7 | | （二）本次发行定价方法和程序 8 | | | 五、本次发行方式的可行性 8 | | | （一）本次发行方式合法合规 8 | | | （二）本次发行程序合法合规 11 | | | 六、本次发行方案的公平性、 ...

成都欧林生物科技股份有限公司 前次募集资金使用情况专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《监管规则适用指引—发行类第 7 号》的相关 规定，成都欧林生物科技股份有限公司（以下简称"本公司"或"公司"）将截 至 2025 年 3 月 31 日止前次募集资金使用情况报告如下： 一、前次募集资金基本情况 （一）实际募集资金金额、资金到位情况 证券代码：688319 证券简称：欧林生物 公告编号：2025-025 经中国证券监督管理委员会《关于同意成都欧林生物科技股份有限公司首次 公开发行股票注册的批复》（证监许可【2021】1397 号）文件核准，公司向社 会公开发行人民币普通股 40,530,000.00 股，实际发行人民币普通股 40,530,000.00 股，发行价为每股人民币 9.88 元。本次募集资金总额为人民币 400,436,400.00 元，扣减含税承销费、保荐费等发行费用人民币 41,599,126.62 元（含税），募 集资金净额为人民币 358,837,273. ...